Abstract
The anti-IgE Omalizumab may be helpful to treat clopidogrel hypersensitivity without stopping thienopyridine administration in patients requirining continuous antiplatellet therapy after coronary stent placement.
Keywords: Clopidogrel, omalizumab, prasugrel, thienopyridines, ticagrelor, urticaria.
Graphical Abstract
[1]
ACC/AHA Guidelines for percutaneous coronary intervention. J. Am. Coll. Cardiol., 2001, 37, 239i-2249i.
[2]
Cheema, A.N.; Mohammad, A.; Hong, T.; Jakubovic, H.R.; Parmar, G.S.; Sharieff, W.; Garvey, M.B.; Kutryk, M.J.; Fam, N.P.; Graham, J.J.; Chisholm, R.J. Characterization of clopidogrel hypersensitivity reactions and management with oral steroids without clopidogrel discontinuation. J. Am. Coll. Cardiol., 2011, 58(14), 1445-1454.
[http://dx.doi.org/10.1016/j.jacc.2011.06.040] [PMID: 21939827]
[http://dx.doi.org/10.1016/j.jacc.2011.06.040] [PMID: 21939827]
[3]
Calogiuri, G.; Mandurino-Mirizzi, A.; Parlangeli, C.; Macchia, L.; Foti, C.; Savage, M.P. Comparing allergist and cardiologist considerations for the optimal management of thienopyridines hypersensitivity. Endocr. Metab. Immune Disord. Drug Targets, 2019, 19(1), 2-12.
[http://dx.doi.org/10.2174/1871530318666180914121758] [PMID: 30215337]
[http://dx.doi.org/10.2174/1871530318666180914121758] [PMID: 30215337]
[4]
Campbell, K.L.; Cohn, J.R.; Fischman, D.L.; Walinsky, P.; Mallya, R.; Jaffrani, W.; Savage, M.P. Management of clopidogrel hypersensitivity without drug interruption. Am. J. Cardiol., 2011, 107(6), 812-816.
[http://dx.doi.org/10.1016/j.amjcard.2010.11.002] [PMID: 21247516]
[http://dx.doi.org/10.1016/j.amjcard.2010.11.002] [PMID: 21247516]
[5]
Siu, H.; Kaliyadan, A.; Fischman, D.L.; Nardone, E.; Poll, D.; Savage, M.P. Use of prasugrel in the setting of clopidogrel hypersensitivity: case report and systematic review of the literature. Platelets, 2016, 27(8), 824-827.
[http://dx.doi.org/10.1080/09537104.2016.1203402] [PMID: 27494368]
[http://dx.doi.org/10.1080/09537104.2016.1203402] [PMID: 27494368]
[6]
Nettis, E.; Cegolon, L.; Di Leo, E.; Canonica, W.G.; Detoraki, A. Omalizumab in elderly patients with chronic spontaneous urticaria: an Italian real-life experience. Ann. Allergy Asthma Immunol., 2018, 120(3), 318-323.
[http://dx.doi.org/10.1016/j.anai.2017.12.007] [PMID: 29508719]
[http://dx.doi.org/10.1016/j.anai.2017.12.007] [PMID: 29508719]
[7]
Mishra, S.; Connors, L.; Tugwell, B. Role of omalizumab in insulin hypersensitivity: a case report and review of the literature. Diabet. Med., 2018, 35(5), 663-666.
[http://dx.doi.org/10.1111/dme.13591] [PMID: 29381818]
[http://dx.doi.org/10.1111/dme.13591] [PMID: 29381818]
[8]
Ali, A.K.; Hartzema, A.G. Assessing the association between omalizumab and arteriothrombotic events through spontaneous adverse event reporting. J. Asthma Allergy, 2012, 5, 1-9.
[http://dx.doi.org/10.2147/JAA.S29811] [PMID: 22690127]
[http://dx.doi.org/10.2147/JAA.S29811] [PMID: 22690127]
[9]
Dobesh, P.P.; Oestreich, J.H. Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy, 2014, 34(10), 1077-1090.
[http://dx.doi.org/10.1002/phar.1477] [PMID: 25164528]
[http://dx.doi.org/10.1002/phar.1477] [PMID: 25164528]
[10]
Harris, J.R.; Coons, J.C. Tigacrelor use in a patient with documented clopidogrel hypersensitivity. Ann. Pharmacother., 2014, 48(9), 1230-1233.
[http://dx.doi.org/10.1177/1060028014539143] [PMID: 24958490]
[http://dx.doi.org/10.1177/1060028014539143] [PMID: 24958490]
[11]
Scala, E.; Giani, M.; Pastore, S.; Pallotta, S.; Guerra, E.C.; Pirrotta, L.; Locanto, M.L.; Frezzolini, A.; De Pità, O.; Puddu, P. Distinct delayed T-cell response to beta-methasone and penicillin-G in the same patient. Allergy, 2003, 58(5), 439-444.
[http://dx.doi.org/10.1034/j.1398-9995.2003.00117.x] [PMID: 12752333]
[http://dx.doi.org/10.1034/j.1398-9995.2003.00117.x] [PMID: 12752333]
[12]
Sánchez-Machín, I.; Iglesias-Souto, J.; Franco, A.; Barrios, Y.; Gonzalez, R.; Matheu, V. T cell activity in successful treatment of chronic urticaria with omalizumab. Clin. Mol. Allergy, 2011, 9, 11.
[http://dx.doi.org/10.1186/1476-7961-9-11] [PMID: 21791043]
[http://dx.doi.org/10.1186/1476-7961-9-11] [PMID: 21791043]
[13]
Walters, K.M.; White, A.A. Tolerance to nonsteroidal anti-inflammatory drugs and alcohol after omalizumab treatment in a patient with chronic urticaria. Ann. Allergy Asthma Immunol., 2016, 117(5), 559-561.
[http://dx.doi.org/10.1016/j.anai.2016.08.020] [PMID: 27788887]
[http://dx.doi.org/10.1016/j.anai.2016.08.020] [PMID: 27788887]
[14]
Aksu, K.; Kurt, E. Aspirin tolerance following omalizumab therapy in a patient with aspirin-exacerbated respiratory disease. Allergol. Immunopathol. (Madr.), 2013, 41(3), 208-210.
[http://dx.doi.org/10.1016/j.aller.2012.02.005] [PMID: 22763305]
[http://dx.doi.org/10.1016/j.aller.2012.02.005] [PMID: 22763305]
[15]
Hayashi, H.; Mitsui, C.; Nakatani, E.; Fukutomi, Y.; Kajiwara, K.; Watai, K.; Sekiya, K.; Tsuburai, T.; Akiyama, K.; Hasegawa, Y.; Taniguchi, M. Omalizumab
reduces cysteinyl leukotriene and 9α,11β-
prostaglandin F2 overproduction in aspirinexacerbated
respiratory disease. J. Allergy Clin. Immunol., 2016, 137(5), 1585-1587.e4.
[http://dx.doi.org/10.1016/j.jaci.2015.09.034] [PMID: 26559322]
[http://dx.doi.org/10.1016/j.jaci.2015.09.034] [PMID: 26559322]
Related Books
Science of Spices and Culinary Herbs - Latest Laboratory, Pre-clinical, and Clinical Studies
Advances in Organic Synthesis
Frontiers in Natural Product Chemistry
Recent Advances in Analytical Techniques
Frontiers in Drug Design and Discovery
Therapeutic Use of Plant Secondary Metabolites
Frontiers in Computational Chemistry
Frontiers in Bioactive Compounds
Photophysics of Supramolecular Architectures
Advances in Organic Synthesis
Article Metrics
21
1